E
0Y5F
vs
S&P 500
S&P 500
Over the past 12 months, 0Y5F has significantly outperformed S&P 500, delivering a return of +37% compared to the S&P 500's +13% growth.
Stocks Performance
0Y5F vs S&P 500
Performance Gap
0Y5F vs S&P 500
Performance By Year
0Y5F vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Endo International PLC
Glance View
Endo International PLC is a specialty pharmaceutical company that operates at the intersection of innovation and necessity within the healthcare industry. Its primary business involves developing, manufacturing, and marketing both branded and generic pharmaceutical products. Endo thrives on a diversified portfolio that spans numerous therapeutic areas, including pain management, urology, orthopedics, and endocrinology. The company strategically positions itself by addressing unmet medical needs, often targeting niche markets where the competition is minimal, thus allowing for premium pricing and robust profit margins. Endo's revenue streams are driven by a blend of proprietary and generic drugs, with a significant portion coming from its well-known brands such as PERCOCET® and SUPPRELIN® LA. Its generics division supplements this by producing cost-effective versions of popular drugs, supporting market accessibility and appealing to cost-sensitive consumers and healthcare providers. By leveraging its research and development capabilities, Endo continues to enhance its product portfolio and explore new market opportunities. The company's growth is rooted in its ability to adapt to the ever-changing regulatory landscape, optimize its operations for efficiency, and forge strategic partnerships that enhance its market reach.
